QTc Prolongation Risk Evaluation in Female COVID-19 Patients Undergoing Chloroquine and Hydroxychloroquine With/Without Azithromycin Treatment

Frontiers in Cardiovascular Medicine

article

Sarah Grewal¹  Lior Jankelson²  Marcel P. H. van den Broek³  Martin Cour⁴  Gloria Bachmann⁵  John B. Kostis⁶  Kamana Misra¹ 

[1] Pharmacovigilance, ContraRx;NYU Langone Health, New York University School of Medicine;Department of Clinical Pharmacy, St. Antonius Hospital;Hôpital Edouard Herriot, Service de Médecine—Intensive Réanimation;Women's Health Institute, Rutgers Robert Wood Johnson Medical School;Cardiovascular Institute, Rutgers Robert Wood Johnson Medical School

关键词: COVID;    QTc changes;    hydroxychloroquine;    chloroquin;    azithromycin (AZM);    QTc;    hydroxychloroquine (HCQ);    women;   

DOI  :  10.3389/fcvm.2020.00152

学科分类：地球科学(综合)

来源: Frontiers

【 摘 要 】

Women have higher risk for developing TdP in response to ventricular repolarization prolonging drugs. Hundreds of trials are administering chloroquine and hydroxychloroquine with/without azithromycin to COVID-19 patients. While an overall prolonged QTc has been reported in COVID-19 patients undergoing these treatments, the question on even higher QTc elevation risk in thousands of female COVID-19 patients undergoing these treatments remains unanswered. We therefore explore data reported and shared with us to evaluate safety and efficacy of antimalaria pharmacotherapies in female COVID-19 patients. Although we observed longer mean QTc intervals in female patients in 2 of the 3 cohorts reviewed, the sex disproportionality in COVID-19 hospitalizations precludes a clear sex mediated QTc interval elevation risk association in the female COVID-19 patients undergoing acute treatment regimens. Adoption of study designs that include observation of sex mediated differential triggering of cardiac electrical activity by these drugs is warranted.

【 授权许可】

CC BY